News Image

Avalo Reports Third Quarter 2024 Financial Results and Recent Business Updates

Provided By GlobeNewswire

Last update: Nov 7, 2024

WAYNE, Pa. and ROCKVILLE, Md., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced business updates and financial results for the third quarter of 2024.

Read more at globenewswire.com

AVALO THERAPEUTICS INC

NASDAQ:AVTX (4/25/2025, 8:00:01 PM)

4.78

-0.1 (-2.05%)



Find more stocks in the Stock Screener

Follow ChartMill for more